2-溴甲基-5-三氟甲基呋喃 | 17515-77-4

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: 2-溴甲基-5-三氟甲基呋喃
• 中文别名: 2-(溴甲基)-5-(三氧甲基)呋喃
• 英文名称: 2-(bromomethyl)-5-(trifluoromethyl)furan
• CAS: 17515-77-4
• 化学式: C₆H₄BrF₃O
• 分子量: 228.996
• InChiKey: YNHVBNGRNNVEMD-UHFFFAOYSA-N

物化性质

• 沸点：
  38 °C
• 密度：
  1.693±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿（微溶）、乙酸乙酯（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  8
• 安全说明：
  S26,S36/37/39,S45
• 危险品运输编号：
  UN 1760
• 海关编码：
  2932190090
• 危险品标志：
  C
• 危险类别码：
  R34
• 包装等级：
  II
• 危险类别：
  8,3
• 危险性防范说明：
  P501,P240,P210,P233,P243,P241,P242,P264,P280,P370+P378,P303+P361+P353,P301+P330+P331,P363,P304+P340+P310,P305+P351+P338+P310,P403+P235,P405
• 危险性描述：
  H226,H314
• 储存条件：
  2-8°C

SDS

Name:	2-(Bromomethyl)-5-(trifluoromethyl)furan 97% Material Safety Data Sheet
Synonym:
CAS:	17515-77-4

Section 1 - Chemical Product MSDS Name:2-(Bromomethyl)-5-(trifluoromethyl)furan 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
17515-77-4	2-(Bromomethyl)-5-(trifluoromethyl)fur	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 17515-77-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 38 - 39 deg C
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H4BrF3O
Molecular Weight: 229

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 17515-77-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(Bromomethyl)-5-(trifluoromethyl)furan - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, N.O.S.*
Hazard Class: 8
UN Number: 1760
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 17515-77-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 17515-77-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 17515-77-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴甲基-5-三氟甲基呋喃 在 三乙基硅烷 、 二苯基-2-吡啶膦 、 偶氮二甲酸二叔丁酯 、 palladium 10% on activated carbon 、 异丙基氯化镁 、 potassium carbonate 、 溶剂黄146 、 三氟乙酸 、 potassium hydroxide 、 (1S,2R,4S,5R)-1-(anthracen-9-ylmethyl)-2-((S)-hydroxy(quinolin-4-yl)methyl)-5-vinyl-1-azoniabicyclo[2.2.2]octane chloride 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 69.92h， 生成 funapide
  参考文献：
  名称：

  ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS

  摘要：

  这项发明涉及某些螺环氧吲哚衍生物的不对称合成，这些衍生物可用于治疗和/或预防钠通道介导的疾病或症状，如疼痛。

  公开号：

  US20130274483A1
• 作为产物：
  描述：

  2-methyl-5-(trifluoromethyl)furan 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 正己烷 为溶剂， 以12.2 g的产率得到2-溴甲基-5-三氟甲基呋喃
  参考文献：
  名称：

  一种2-卤甲基-5-三氟甲基呋喃的合成方法

  摘要：

  本发明公开了一种2‑卤甲基‑5‑三氟甲基呋喃的合成方法，以乙酰丙酸酯类为原料，具体合成方法为将乙酰丙酸酯类与脂肪二醇反应得到化合物1，然后将化合物1和三氟甲基三甲基硅烷混合低温加入季铵氟化盐反应，再加热水解后得到化合物2，然后将氯化胆碱和尿素按摩尔比1：2混合搅拌，加入化合物2反应处理后得到含有化合物3的溶液，再在含有化合物3的溶液中加入卤代试剂和自由基引发剂反应得到产物2‑卤甲基‑5‑三氟甲基呋喃；本方法路线简捷，操作方便，无危险试剂的使用，具有很好的工业化前景。

  公开号：

  CN115353499A
• 作为试剂：
  描述：

  2-溴甲基-5-三氟甲基呋喃 、 6’H-spiro[indoline-3,7’-[1,3]dioxolo[4,5-f]benzofuran]-2-one 在 2-溴甲基-5-三氟甲基呋喃 作用下， 生成 1'-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one
  参考文献：
  名称：

  SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS

  摘要：

  本发明涉及制备某些螺环氧吲哚衍生物的方法，该衍生物可用于治疗和/或预防钠通道介导的疾病或症状，例如疼痛。

  公开号：

  US20110087027A1

文献信息

• A Photochemical Organocatalytic Strategy for the α‐Alkylation of Ketones by using Radicals
  作者：Davide Spinnato、Bertrand Schweitzer‐Chaput、Giulio Goti、Maksim Ošeka、Paolo Melchiorre

  DOI：10.1002/anie.201915814

  日期：2020.6.8

  Reported herein is a visible‐light‐mediated radical approach to the α‐alkylation of ketones. This method exploits the ability of a nucleophilic organocatalyst to generate radicals upon SN2‐based activation of alkyl halides and blue light irradiation. The resulting open‐shell intermediates are then intercepted by weakly nucleophilic silyl enol ethers, which would be unable to directly attack the alkyl

  本文报道了一种可见光介导的自由基对酮进行α-烷基化的方法。该方法利用了亲核有机催化剂在S N上生成自由基的能力基于2的烷基卤化物的激活和蓝光照射。然后，所得的开壳中间体被弱亲核的甲硅烷基烯醇醚截获，它们将无法通过传统的双电子路径直接攻击卤代烷。温和的反应条件使酮的α位置具有与经典阴离子策略不兼容的官能团。此外，该方法的氧化还原中性性质使其与基于金鸡纳酮的伯胺催化剂兼容，该催化剂被用于开发酮的对映选择性有机催化自由基α-烷基化的罕见实例。
• Synthesis and structure activity relationship of the first class of LXR inverse agonists
  作者：Bahaa Elgendy、Kristine Griffett、Lamees Hegazy、Paolo Di Fruscia、Kirby Sample、Emmalie Schoepke、Theodore M. Kamenecka、Thomas P. Burris

  DOI：10.1016/j.bioorg.2021.105540

  日期：2022.2

  anticancer activity of SR9243 (7) and this suggests that new inverse agonists have great potential as anticancer agents. We identified compounds with distinct selectivity toward both LXR isoforms, which can be excellent tools to study the pharmacology of both isoforms. We employed molecular dynamic (MD) simulations to better understand the molecular mechanism underlying inverse agonist activity and to

  肝 X 受体 (LXR) 是核受体家族的成员，它们在脂质和胆固醇代谢中发挥重要作用。此外，它们是几种炎症途径的关键调节剂。LXRs 的药理调节在治疗代谢疾病、神经退行性疾病和癌症方面具有巨大潜力。我们是第一组鉴定出 LXR 反向激动剂 SR9238 ( 6 ) 和 SR9243 ( 7 ) 并证明了它们在治疗肝病和癌症方面的潜在效用。在这里，我们展示了基于 SR9238 ( 6 ) 和 SR9243 ( 7 ) 的结构-活性关系 (SAR) 研究结果。这项研究确定了16、17、19和38，它们是比 SR9238 ( 6 ) 和 SR9243 ( 7 ) 更有效的反向激动剂，并抑制 DU145 细胞中脂肪酸合酶基因的表达。我们之前证明了 FASN 的抑制与 SR9243 ( 7 ) 的抗癌活性相关，这表明新的反向激动剂具有作为抗癌剂的巨大潜力。我们鉴定了对两种 LXR 异构体具有不同选择性的
• [EN] HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME<br/>[FR] COMPOSÉS HÉTÉROARYLE UTILES EN TANT QU'INHIBITEURS DE L'ENZYME D'ACTIVATION SUMO
  申请人：DUFFEY MATTHEW O

  公开号：WO2016004136A1

  公开（公告）日：2016-01-07

  Disclosed are chemical entities which are compounds of formula (I); or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra', Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

  公开了公式(I)的化合物或其药物可接受的盐； 其中Y、Ra、Ra'、Rb、Rc、X1、X2、X3、Rd、Z1和Z2具有本文所述的值，并且星号位置表示的立体化学配置指示绝对立体化学。 根据本公开的化学实体可用作Sumo激活酶（SAE）的抑制剂。 进一步提供了包含本公开化合物的药物组合物以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或病症的方法。
• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009067613A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物，式(I)。其中R1、R2、R3、R4和L1在规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物，式(II)。其中R1a、R2a、Rx和n如规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• Pyrazolones as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Banner Lester Bruce

  公开号：US20070049632A1

  公开（公告）日：2007-03-01

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式(I)的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。